Business Wire

Tsing Hua University Hospital Preparatory Office Officially Opens in Taoyuan

Share

On August 20, the Tsing Hua University Hospital Preparatory Office was officially opened in the Xinkong Building at the Taoyuan Metro Corporation’s Qingpu Depot, which is only one MRT station away from the site where the Hospital will be built.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005421/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

At the opening ceremony (right to left): NTHU senior vice presidents Tai Nyan-hwa and Lyu Ping-chiang, NTHU president W. John Kao, Taoyuan City mayor Cheng Wen-tsan, former NTHU president Hocheng Hong, Taoyuan Metro chairman Liu Kun-I, and Taoyuan Aerotropolis chairman Chen Si-jhen. (Photo: National Tsing Hua University)

NTHU and the Taoyuan City Government have already signed a letter of intent outlining their plan to jointly establish a world-class medical center that will serve the local community; the plan also includes assistance in the training of bilingual teachers and support for science education and experimental education at Taoyuan’s kindergartens, primary, and secondary schools.

The Preparatory Office was officially inaugurated by Taoyuan City mayor Cheng Wen-tsan and NTHU president W. John Kao.

Mayor Cheng has played a key role in the early stages of the Hospital project. He pointed out that Taiwan is good at both electronics and medical care, both of which are taught at NTHU, and that’s why he has been such a staunch supporter of NTHU through all the difficulties which have arisen in the planning stage.

Cheng emphasized that it will take only ten minutes for an ambulance to go from the Taoyuan International Airport to the emergency room at the new hospital; and that in addition to cosmetic surgery and health examinations, the Hospital will also provide critical care and boron neutron capture therapy (BNCT).

Moreover, the Hospital is expected to become a leading center for the development of advanced cell regeneration technology.

President Kao said that this is a very important day for NTHU, in that the school has long had its sights set on medical education, and now the dream has finally come true, noting that “Today is a new milestone in this 50-kilometer journey from NTHU to Taoyuan, which has been going on for some 66 years.”

Kao also noted that this year could be seen as the “year of medicine” at NTHU, since the first batch of medical students has recently been enrolled.

The Hospital will be located near the Hengshan Station (A16) of the Airport MRT line, on a parcel of land provided by Taoyuan City. The size of the parcel is 7.2 hectares, of which 5 hectares will be used for the Hospital itself, while the remaining 2.2 hectares will be used for the affiliated teaching and research facilities.

NTHU senior vice president Lyu Ping-chiang said that the BOT agreement will be finalized by the end of this year, and that construction will start next year, soon after the parcel is transferred. The Hospital is expected to be completed by the end of 2027 and opened in 2028.

The Hospital will initially have 200 general acute care beds, plus an intensive care unit, a respiratory care unit, negative pressure isolation rooms, and a psychiatric unit for both inpatients and outpatients, all of which will be gradually expanded over a number of years to reach a total capacity of 910 beds.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Hsueh
NTHU
(886)3-5162006
hoyu@mx.nthu.edu.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye